Ask about this productRelated genes to: ERBB3 antibody
- Gene:
- ERBB3 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 3
- Previous symbol:
- LCCS2
- Synonyms:
- HER3
- Chromosome:
- 12q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-07-15
- Date modifiied:
- 2019-04-23
Related products to: ERBB3 antibody
Related articles to: ERBB3 antibody
- Pseudokinase domains (PsKDs) mediate key signaling processes involved in human disease. Despite transformative success in targeting catalytically active protein kinases, drug development for pseudokinases has lagged behind. Although they lack catalytic activity, pseudokinases are conformationally dynamic and are thought to function by switching between conformations that bind different signaling partners. This conformational switching model suggests the possibility of modulating pseudokinase signaling using small molecules that alter or bias conformational transitions. Focusing on the three PsKDs in receptor tyrosine kinases (RTKs) that retain nucleotide binding (ErbB3, EphB6, and EphA10), we used hydrogen-deuterium exchange mass spectrometry (HDX-MS) to ask whether different small molecules can promote distinct changes in conformation or dynamics. We detected distinct conformational effects in different locations within the PsKDs when different small molecules bind their respective ATP-binding sites. Our results suggest that similar small molecules will be useful probes for understanding pseudokinase function and ultimately for developing possible therapeutics. - Source: PubMed
Publication date: 2026/09/18
Sheetz Joshua BTsutsui YukoAshtekar Kumar DMathea SebastianKnapp StefanLemmon Mark A - - Source: PubMed
Publication date: 2026/09/18
Rodrigues-Junior Dorival MendesSáez-Ibáñez Ana RosaScheffler Julia MTerabayashi TakeshiDaubel NinaMäkinen TaijaIdevall-Hagren OlofMoustakas AristidisFerby Ingvar - A novel entity of ERBB2/ERBB3-mutated S100/SOX10-positive uterine sarcoma has recently been proposed. However, the detailed clinicopathologic spectrum and molecular features of this emerging entity remain to be further elucidated. Here, we describe 6 cases of ERBB2-altered uterine sarcoma. The patients ranged from 41 to 65 years old (median, 48 years). Most tumors (5/6; 83.3%) were centered in the cervical stroma. An infiltrative, interdigitating border was a consistent finding, with neoplastic cells intimately admixed with entrapped pre-existing smooth muscle fascicles. The tumor exhibits alternating hypercellular and hypocellular areas. Most cases (5/6; 83.3%) showed a predominantly spindled architecture arranged in a fascicular, herringbone, or storiform pattern. The tumor cells typically showed mild-to-moderate cytologic atypia, scant cytoplasm, and a brisk mitotic count (median: 28.5/10 HPFs). Intriguingly, the remaining case (1/6; 16.7%) harbored a concurrent TP53 nonsense mutation and exhibited a predominantly epithelioid architecture with marked cytological atypia. Notably, another distinctive finding was the presence of neoplastic multinucleated giant cells exhibiting a characteristic floret-like nuclear arrangement in all cases. The background stroma exhibited focal myxoid change, hyalinization, and variable inflammatory infiltrates. All cases exhibited strong and diffuse positivity for S100 and SOX10. Next-generation sequencing revealed a highly recurrent molecular signature characterized by universal oncogenic ERBB2 missense mutations (including the canonical V777L variant as well as other activating mutations) and CDKN2A copy number loss, frequently accompanied by inactivating ATRX mutations (66.7%), CDKN2B (66.7%), MTAP (50.0%) copy number loss, ERBB3 mutations (50.0%), and concurrent ERBB2 amplification (33.3%). Of the 6 patients, 1 (harboring a TP53 nonsense mutation) had bone metastasis at diagnosis and was lost to follow-up, 2 progressed at 3.5 and 5 months (one death at 10 months), and 3 remained alive with no evidence of disease at 10-12 months. Our results support this emerging entity as a distinct, aggressive gynecologic mesenchymal neoplasm harboring actionable ERBB2 alterations. - Source: PubMed
Publication date: 2026/09/17
Lyu ZhuoyaoHan WenqiLi HuiLiang XiaolongSu XinWu Huanwen - Human epidermal growth factor receptor (HER) 3, encoded by the gene, transduces signals most effectively when dimerized with HER2. Although HER3 protein expression has been considered a poor prognostic factor in ovarian cancer, limited data exist on changes in HER3 protein expression and messenger RNA (mRNA) expression during recurrence. This study evaluated HER3/ERBB3 expression before and after recurrence and its association with prognosis using paired samples. We also evaluated HER2/ERBB2 expression. - Source: PubMed
Publication date: 2026/09/11
Yokosu KotaYamashita RiuFujii SatoshiTanabe HiroshiMukohara ToruSato SaoriKobayashi MakiOshima KeikoKimura HirokoTakahashi HiroyukiSaito MotoakiYamada KyosukeTakano HirokuniOkamoto AikouHarano Kenichi
- Source: PubMed